The shift in tuberculosis timing among people living with HIV in the course of antiretroviral therapy scale-up in Malawi.


Journal

Journal of the International AIDS Society
ISSN: 1758-2652
Titre abrégé: J Int AIDS Soc
Pays: Switzerland
ID NLM: 101478566

Informations de publication

Date de publication:
04 2019
Historique:
received: 12 08 2018
accepted: 17 12 2018
entrez: 1 5 2019
pubmed: 1 5 2019
medline: 14 4 2020
Statut: ppublish

Résumé

Although the use of antiretroviral therapy (ART) reduces HIV-associated tuberculosis (TB), patients living with HIV receiving ART remain at a higher risk of developing TB compared to those without HIV. We investigated the incidence of TB and the proportion of HIV-associated TB cases among patients living with HIV who are receiving ART. The study used TB registration and ART programme data collected between 2008 and 2017 from an integrated, public clinic in urban Lilongwe, Malawi. ART initiation was based on either WHO clinical staging or CD4 cell count. The CD4 thresholds for ART initiation eligibility was initially 250 cells/μL then changed to 350 cells/μL in 2011, 500 cells/μL in 2014 and to universal treatment upon diagnosis from 2016. Using TB registration data, we calculated the proportion of TB/HIV patients who were already on ART when they registered for TB treatment by year of TB registration. ART registration data were used to examine TB incidence by calendar year of ART follow-up and by time on ART. The overall proportion of TB/patients living with HIV who started TB treatment while on ART increased from 21% in 2008 to 81% in 2017 but numbers remained relatively constant at 500 TB cases annually. The overall incidence rate of TB among patients on ART was 1.35/100 person-years (95% CI 1.28 to 1.42). The incidence of TB by time on ART decreased from 6.4/100 person-years in the first three months of ART to 0.4/100 person-years after eight years on ART. TB incidence was highest in the first month on ART. The annual rate of TB among patients on ART rapidly decreased each calendar year and stabilized at 1% after 2013. Although the risk of developing TB decreased with year of ART initiation in univariable analysis, there was no significant association after adjusting for sex, age and reason for ART eligibility. The decline in TB incidence over calendar years suggests protective effects of early ART initiation. The high TB incidence within the first month of ART highlights the need for more sensitive tools such as X-ray and GeneXpert to identify patients living with HIV who have clinical and subclinical TB disease at ART initiation.

Identifiants

pubmed: 31038836
doi: 10.1002/jia2.25240
pmc: PMC6490056
doi:

Substances chimiques

Anti-HIV Agents 0
Antitubercular Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e25240

Informations de copyright

© 2019 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.

Références

Lancet. 2018 Jul 28;392(10144):292-301
pubmed: 30032978
AIDS. 2007 Jul 11;21(11):1441-8
pubmed: 17589190
AIDS. 2009 Aug 24;23(13):1717-25
pubmed: 19461502
Crit Ultrasound J. 2012 Nov 21;4(1):21
pubmed: 23171481
Eur Respir J. 2015 Feb;45(2):547-9
pubmed: 25395030
AIDS. 2009 Mar 13;23(5):631-6
pubmed: 19525621
Trop Med Int Health. 2011 Nov;16(11):1397-403
pubmed: 21806742
AIDS. 2007 Mar 30;21(6):713-9
pubmed: 17413692
Lancet Infect Dis. 2010 Jul;10(7):489-98
pubmed: 20610331
J Int AIDS Soc. 2019 Apr;22(4):e25240
pubmed: 31038836
Lancet. 2011 May 7;377(9777):1588-98
pubmed: 21492926
Lancet Infect Dis. 2008 Aug;8(8):516-23
pubmed: 18652998
PLoS Med. 2012;9(7):e1001270
pubmed: 22911011
J Infect Dis. 2008 Jul 1;198(1):90-4
pubmed: 18498237
J Acquir Immune Defic Syndr. 2012 Aug 15;60 Suppl 3:S136-44
pubmed: 22797735
J Acquir Immune Defic Syndr. 2011 Aug 1;57(4):311-8
pubmed: 21423023
PLoS One. 2012;7(3):e34156
pubmed: 22479548
J Int AIDS Soc. 2017 Jun 23;20(1):21327
pubmed: 28691438
Lancet. 2014 Aug 23;384(9944):682-90
pubmed: 24835842

Auteurs

Hannock Tweya (H)

The International Union Against Tuberculosis and Lung Disease, Paris, France.
Lighthouse Trust, Lilongwe, Malawi.

Caryl Feldacker (C)

International Training and Education Center for Health, University of Washington, Seattle, WA, USA.
Department of Global Health, University of Washington, Seattle, WA, USA.

James Mpunga (J)

National Tuberculosis Control Programme, Community Health Science Unit, Lilongwe, Malawi.

Henry Kanyerere (H)

National Tuberculosis Control Programme, Community Health Science Unit, Lilongwe, Malawi.

Tom Heller (T)

Lighthouse Trust, Lilongwe, Malawi.

Prakash Ganesh (P)

Lighthouse Trust, Lilongwe, Malawi.

Dave Nkosi (D)

Bwaila District Hospital, Lilongwe, Malawi.

Mike Kalulu (M)

Lighthouse Trust, Lilongwe, Malawi.

George Sinkala (G)

Lighthouse Trust, Lilongwe, Malawi.

Thomas Satumba (T)

Lighthouse Trust, Lilongwe, Malawi.

Sam Phiri (S)

Lighthouse Trust, Lilongwe, Malawi.
Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, USA.
Department of Public Health, College of Medicine, School of Public Health and Family Medicine, University of Malawi, Zomba, Malawi.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH